Tests colchicine in people with heart failure and a blood-cell gene change
Tests colchicine in adults with reduced-function heart failure and CHIP gene mutations.
Key facts
- Who runs it
- Goethe University Frankfurt
- Where
- Frankfurt Am Main, GermanySee the site
- Registry title
- Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 17 Feb 2022
- Planned end
- 1 Mar 2026
- Type of study
- Interventional
- Record updated
- 5 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure from a damaged heart muscle after reduced blood flow, with a weak pumping heart, and with known CHIP gene changes (DNMT3A and TET2).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Ischemic cardiomyopathy with reduced left ventricular function (LVEF 40% or lower). Stable heart failure, NYHA II-III.
- Earlier treatment
- Constant optimal evidence-based medical treatment for at least 4 weeks.
- Biomarker or test result
- Known status of CHIP mutations (DNMT3A and TET2).
Main reasons for not taking part
- Acute decompensated heart failure (NYHA IV)
- Known intolerance to Colchicine
- Heart failure not caused by reduced blood flow to the heart
- Acute coronary syndrome or invasive procedure within three months before joining
- Active cancer or active infection
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients (m/f) age >/=18
- Ischemic cardiomyopathy with reduced left ventricular function (LVEF </= 40%)
- Stable heart insufficiency (NYHA II-III) under constant (at least 4 weeks) optimal evidence based medical treatment
- Known status of CHIP mutations (DNMT3A and TET2)
- Signed Informed Consent after detailed information
- Negative pregnancy testing, high effective method of contraception (women of child bearing potential)
Who cannot take part
- Acute coronary syndromes within three months prior to inclusion
- Invasive procedure within three months prior to inclusion
- Acute decompensated heart failure (NYHA IV; HF>110 bpm; systolic blood pressure < 90mmHg
- Non ischemic etiology of heart failure
- Active malignancy
- Ejection fraction > LVEF 40%
- Active infection (hs-CRP > 10 mg/dl)
- Liver cirrhosis, CHILD C (ALT < 60 U/l; AST < 60 U/l; Total Bilirubin < 2 mg/dl)
- Renal insufficiency grade 5 (GFR<15 ml/min/1.73m²)
- Known intolerance to Colchicine
Where in Germany
- Goethe University FrankfurtFrankfurt Am Main, GermanyNot yet recruiting
About the trial
What the trial wants to find out
Efficay and safety of Colchicine in patients with HFrEF and clonal hematopoiesis of indeterminate potential - effects on endothelial cell function, inflammatory biomarkers and inflammatory genetic signatures
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)
- Plain-language title
- Tests colchicine in people with heart failure and a blood-cell gene changeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 November 2024